<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82497">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02147548</url>
  </required_header>
  <id_info>
    <org_study_id>ETILANCE - ETI 175</org_study_id>
    <nct_id>NCT02147548</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly</brief_title>
  <official_title>Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly. A Monocentric, Randomized, Cross-over, Double-blind Clinical Study Versus Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocodex</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocodex</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of etifoxine (an anxiolytic) compared
      to lorazepam (a benzodiazepine anxiolytic) on vigilance and cognitive functions in the
      elderly.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Reaction time (RTI) of Cambridge Neuropsychological Test Automated Batteries (CANTAB)</measure>
    <time_frame>2 hours after the study treatment intake</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>etifoxine (Anxiolytic)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>etifoxine, 100 mg, a single oral intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lorazepam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lorazepam, 2 mg, a single oral intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 capsules of Placebo, a single oral intake</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etifoxine</intervention_name>
    <arm_group_label>etifoxine (Anxiolytic)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lorazepam</intervention_name>
    <arm_group_label>lorazepam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman aged from 65 to 75 years

          -  Right-handed subject (Edinburgh Handedness inventory)

          -  Subject having signed the consent form

          -  Subject having agreed to be listed on the French National Healthy Volunteers database

          -  Subject affiliated or beneficiary to French social insurance

        Exclusion Criteria:

          -  Subject presenting a neurological or psychiatric disease notably cognitive,
             progressing

          -  Anxious subject (Hamilton score &gt; 7 and/or Spielberger score &gt; 51 for a man or &gt; 61
             for a woman)

          -  Left-handed subject (Edinburgh Handedness inventory)

          -  Subject presenting a not corrected visual disease or a motor function disease that
             could interfere with tests realization

          -  Smoker

          -  Subject taking one or more psychotropics or apparent products

          -  Subject having taken, during the previous month, one or more drugs that could
             interfere with study drugs metabolism

          -  Subject drinking too much coffee or tea (&gt; 4 cups per day) or alcohol (&gt;½ liter of
             wine or equivalent per day)

          -  Subject presenting contra-indication to one of the drugs used in the study

          -  Subject with past history of intolerance to drugs used in the study

          -  Subject not capable to use the CANTAB cognitive evaluation system

          -  Subject which may not be able to participate to the whole study

          -  Subject under tutelage or guardianship

          -  Subject not able to well-understand French and so to understand cognitive tests

          -  Subject not capable to swallow capsules

          -  Subject participating to another study or in exclusion period (3 months after a
             previous trial).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pr DEPLANQUE Dominique, MD, PhD</last_name>
    <phone>0033320445449</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>DEPLANQUE Dominique, MD, PhD</last_name>
    <phone>0033320445449</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique, CIC 1403 INSERM/CHRU</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DEPLANQUE Dominique, MD, PhD</last_name>
      <phone>0033320445449</phone>
      <email>dominique.deplanque@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>DEPLANQUE Dominique, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 22, 2014</lastchanged_date>
  <firstreceived_date>May 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lorazepam</mesh_term>
    <mesh_term>Etifoxine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
